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Abstract
Introduction Dysregulation of coagulation and local fibrinolysis
found in patients with acute lung injury often results in the need
for the support of mechanical ventilation. High-tidal-volume
mechanical ventilation can increase lung damage and
suppression of fibrinolytic activity, but the mechanisms are
unclear. We hypothesized that subcutaneous injections of
unfractionated heparin and enoxaparin would decrease
neutrophil infiltration, lung edema, and plasminogen-activator
inhibitor-1 (PAI-1) production in mice exposed to high-tidal-
volume ventilation.
Methods Male C57BL/6 mice, weighing 20 to 25 g, were
exposed to either high-tidal-volume (30 ml/kg) or low-tidal-
volume (6 ml/kg) mechanical ventilation with room air for 1 to 5
hours after 200 IU/kg or 400 IU/kg unfractionated heparin and
4 mg/kg or 8 mg/kg enoxaparin administration. Nonventilated
mice served as a control group. Evan blue dye, lung wet- to dry-
weight ratio, histopathologic grading of epithelium,
myeloperoxidase, and gene expression of PAI-1 were measured.
The expression of PAI-1 was studied by immunohistochemistry.
Results High-tidal-volume ventilation induced increased
microvascular permeability, neutrophil influx, PAI-1 mRNA
expression, production of PAI-1 protein, and positive staining of
PAI-1 in epithelium in a dose-dependent manner. Lung injury
induced by high-tidal-volume ventilation was attenuated with
PAI-1-deficient mice and pharmacologic inhibition of PAI-1
activity by low-dose unfractionated heparin and enoxaparin.
Conclusions We conclude that high-tidal-volume mechanical
ventilation increased microvascular permeability, neutrophil
influx, lung PAI-1 mRNA expression, production of active PAI-1.
The deleterious effects were attenuated by low-dose
unfractionated heparin or enoxaparin treatment. Understanding
the protective mechanism of unfractionated heparin and
enoxaparin related to the reduction of PAI-1 may afford further
knowledge of the effects of mechanical forces in the lung and
development of possible therapeutic strategies involved in acute
lung injury.
ALI: acute lung injury; ARDS: acute respiratory distress syndrome; BAL: bronchoalveolar fluid; DAB: diaminobenzidine; EBD: Evans blue dye; ES: 
embryonic stem cells; GAPDH: glyceraldehyde-phosphate dehydrogenase; H&E: hematoxylin and eosin; IHC: immunohistochemistry; LPS: lipopoly-
saccharide; LMWH: low-molecular-weight heparin; MIP-2: macrophage inflammatory protein-2; MPO: myeloperoxidase; PaCO2: arterial carbon diox-
ide pressure; PaO2: arterial oxygen pressure; PAF: platelet-activating factor; PAI-1: plasminogen activator inhibitor-1; RT-PCR: reverse transcription-
polymerase chain reaction; TGF-β1: transforming growth factor-β1; TMB: 3,3', 5,5'-tetramethylbenzidine; TNF-α: tumor necrosis factor-alpha; tPA: 
tissue-type plasminogen activator; uPA: urokinase-type plasminogen activator; VILI: ventilator-induced lung injury; VT: tidal volume.Critical Care    Vol 13 No 4    Li et al.
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Introduction
Acute respiratory distress syndrome (ARDS) is an inhomoge-
neous lung disease characterized by neutrophil influx into the
lungs, increased expression of inflammatory cytokines or
chemokines, loss of epithelial and endothelial integrity, and the
development of alveolar and interstitial pulmonary edema [1].
The use of high tidal volume in normal animals mimics this
overdistention of the normal lung. Mechanical ventilation with
high tidal volumes (VT) causes acute lung injury (VILI, ventila-
tor-induced lung injury) characterized by an inflammatory
response that is morphologically and histologically similar to
that caused by bleomycin or bacterial lipopolysaccharide
[2,3]. High-tidal-volume ventilation can lead to the production
of inflammatory cytokines, including plasminogen activator
inhibitor-1 (PAI-1), transforming growth factor-β1 (TGF-β1),
and murine macrophage inflammatory protein-2 (MIP-2);
apoptosis of airway epithelial cells; lung neutrophil influx; and
capillary leak [4,5].
Intraalveolar fibrin formation in acute lung injury occurs after
capillary alveolar leakage of plasma fibrinogen, activation of
coagulation, and suppression of local fibrinolysis, activating
endothelial cells to produce proinflammatory mediators, and
eliciting recruitment and activation of neutrophils. Local pro-
duction of PAI-1 has been found to suppress the fibrinolytic
activity in bronchoalveolar fluid (BAL) from patients with ARDS
supported by high-tidal-volume mechanical ventilation [6].
PAI-1, a member of the serine protease inhibitor (serpin) gene
family, rapidly inhibits both urokinase-type plasminogen activa-
tor (uPA) and tissue-type plasminogen activator (tPA) [7]. PAI-
1 also forms complexes with other serine proteases involved
in the coagulation cascade, including factors Xa, XIa, XIIa, kal-
likrein, and thrombin, especially in the presence of cofactors of
heparin or vitronectin [8].
Enoxaparin, one of the low-molecular-weight heparins
(LMWHs), is safer and easier to administer than unfraction-
ated heparin, a naturally occurring glycosaminoglycan with
both anticoagulant and antiinflammatory activities [9]. LMWH
was found in a porcine acute lung injury model to have protec-
tive effects because of its effects on neutrophil emigration,
edema formation, tumor necrosis factor-α (TNF-α), and throm-
boxane B2 production [10,11]. Previous studies showed the
protective effects of heparin in animal models of lung injury
[9,10]. In this high-tidal-volume ventilation-induced acute lung
injury model in mice, we compare the effects between different
doses of low-molecular-weight and unfractionated heparin,
and correlation of acute lung injury to production of PAI-1 by
using animals deficient in PAI-1. We hypothesized that subcu-
taneous injections of unfractionated heparin or enoxaparin
would decrease neutrophil infiltration, lung edema, and PAI-1
production in mice exposed to high-tidal-volume ventilation.
Materials and methods
Experimental animals
Male C57BL/6, either wild-type PAI-1+/+  or PAI-1-/-  on a
C57BL/6 background, aged between 6 and 8 weeks, weigh-
ing between 20 and 25 g, were obtained from Jackson Labo-
ratories (Bar Harbor, ME, USA) and the National Laboratory
Animal Center (Taipei, Taiwan). Mice that are homozygous for
the targeted mutation are viable and fertile and do not display
any gross behavioral abnormalities. The disruption of the
Serpine1 gene induces a mild hyperfibrinolytic state. Com-
pared with that in wild-type mice, pulmonary clot lysis is
increased in the homozygote. Endotoxin-induced venous
thrombosis is decreased compared with that in wild-type mice
[12]. The construct PAI-1, containing a PGK-neomycin resist-
ance cassette, replaced all of the serpine1 coding sequence
and part of the promoter region, including the transcription-ini-
tiation site and is electroporated into 129S2/SvPas-derived
E3 embryonic stem (ES) cells. Injection of the ES cells into
C57BL/6 (B6) blastocysts generated chimeras. The resulting
chimeric male animals were crossed to C57BL/6 mice, and
then backcrossed to the same for eight generations. The lower
expressions of the PAI-1 protein in PAI-1-/- mice was confirmed
by using Western blot analysis. The study was performed in
accordance with the animal experimental guidelines of the
National Institutes of Health and with the approval of the local
research committee.
Experimental groups
The experimental group of animals and procedures used in this
study is summarized in Table 1.
Ventilator protocol
We used our established mouse model of VILI, as previously
described [13,14]. A 20-gauge angiocatheter was introduced
into the tracheotomy orifice of mice under general anesthesia
with intraperitoneal ketamine (90 mg/kg) and xylazine (10 mg/
kg). The mice were placed in a supine position on a heating
blanket and then attached to a Harvard apparatus ventilator,
model 55–7058 (Harvard Apparatus, Holliston, MA, USA), set
to deliver either 6 ml/kg at a rate of 135 breaths per minute or
30 ml/kg at a rate of 65 breaths per minute, for 1 and 5 hours
while breathing room air with zero end-expiratory pressure.
The mice then received 0.9% saline containing maintenance
ketamine (0.1 mg/g/h) and xylazine (0.01 mg/g/h) at a rate of
0.09 ml/10 g/h by a continuous intraperitoneal fluid pump. The
tidal volume delivered by the ventilator was checked by fluid
displacement from an inverted calibration cylinder. Continuous
monitoring of end-tidal CO2 by a microcapnograph (Columbus
Instruments, Columbus, OH, USA) was performed, and respi-
ratory frequencies of 135 breaths per minute for 6 ml/kg and
65 breaths per minute for 30 ml/kg were chosen in the exper-
iment, with end-tidal CO2 at 30 to 40 mm Hg. Airway peak
inspiratory pressure was measured with a pressure-transducer
amplifier (Gould Instrument Systems, Valley View, OH, USA)
connected to the tubing at the proximal end of the tracheos-Available online http://ccforum.com/content/13/4/R108
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tomy. Mean arterial pressure was monitored every hour during
mechanical ventilation by using the same pressure-transducer
amplifier connected to a 0.61-mm outer diameter (0.28-mm
inner diameter) polyethylene catheter ending in the common
carotid artery. At the end of the study period, heparinized
blood was taken from the arterial line for analysis of arterial
blood gas, and the mice were killed. Control, nonventilated
mice were anesthetized and killed immediately.
Unfractionated heparin and enoxaparin administration
Unfractionated heparin (Sigma, St. Louis, MO, USA), 200 IU/
kg or 400 IU/kg, and enoxaparin (Sigma), 4 mg/kg or 8 mg/kg,
were given subcutaneously 30 minutes before ventilation,
based on previous in vivo studies that showed that 200 IU/kg
heparin and 4 mg/kg enoxaparin inhibited blood coagulation
and lung injury [9,15].
Evans Blue dye analysis
Extravasation of Evans blue dye (EBD; Sigma) into the intersti-
tium was used as a quantitative measure of changes of micro-
vascular permeability in acute lung injury [13]. Thirty minutes
before the end of mechanical ventilation, 30 mg/kg of Evans
blue dye was injected through the internal jugular vein. At the
time of death after 5 hours of mechanical ventilation, the lungs
were perfused, free of blood, with 1 ml of 0.9% normal saline
via the right ventricle and removed en bloc. Evans blue was
extracted from lung tissue after homogenization for 2 minutes
in 5 ml of formamide (Sigma) and incubated at 37°C overnight.
The supernatant was separated by centrifugation at 5,000 g
for 30 minutes, and the amount was recorded. Evans blue in
the plasma and lung tissue was quantitated by dual-wave-
length spectrophotometric analysis at 620 and 740 nm. The
method corrects the specimen's absorbance at 620 nm for the
absorbance of contaminating heme pigments, by using the fol-
lowing formula:
We calculated the Evans blue dye amount extracted from lung
tissue and divided the amount by the weight of the lung tissue.
Analysis of lung water
Lungs were removed en bloc, and large airways were
removed. Both lungs were weighed and then dried in an oven
at 80°C for 48 hours. If no changes were found in the dry lung
weight at 24 and 48 hours, the weight at 48 hours was used.
Lung wet- to dry-weight ratio was used as an index of pulmo-
nary edema formation [16].
Histopathologic grading of VILI
The lung tissues from control, nonventilated mice and mice
exposed to high- or low-tidal-volume ventilation for 5 hours
while breathing room air were removed en bloc and filled with
10% neutral buffered formalin (pH 6.8 to 7.2) at 30-cm H2O
pressure via polyethylene tubing inserted into the trachea. The
lungs were paraffin embedded, sliced at 4 μm, stained with
hematoxylin and eosin, and reviewed from 10 nonoverlapping
fields by a single investigator blinded to the mouse genotype.
Lung injury was scored by using the average of the following
items: alveolar congestion, hemorrhage, infiltration of neu-
trophils into airspace or the vessel wall, and thickness of the
alveolar wall [17]. A score of 0 represented normal lungs; 1,
Corrected absorbance at  Actual absorbance 
at   nm
620
620 1
=
−[. . ( ) . ] . 426 740 0 03 absorbance at  +
Table 1
Experimental groups and procedure of animals per group
EBD
(5 hours)
Lung water, PAI-1
(5 hours)
Neutrophils, MPO
(5 hours)
PAI-1 mRNA
(1 hour)
IHC, H&E stain
(5 hours)
C o n t r o l 6 666 6
VT6  m l / k g 6 666 6
VT3 0  m l / k g 6 666 6
VT30 ml/kg
+ 200 IU/kg UFH
6 666 6
VT30 ml/kg
+ 400 IU/kg UFH
6 666 6
VT30 ml/kg
+ 4 mg/kg enoxaparin
6 666 6
VT30 ml/kg
+ 8 mg/kg enoxaparin
6 666 6
VT30 ml/kg
+ PAI-1-/-
6 666 6
Control = spontaneously breathing, nonventilated mice; EBD = Evans blue dye, a measurement of microvascular leak in the lung; H&E = 
hematoxylin and eosin; IHC = immunohistochemical stain; lung water = measured by lung wet- to dry-weight ratio; MPO = myeloperoxidase, a 
measurement of total neutrophil infiltration in the lung; PAI-1 = plasminogen-activator inhibitor-1; UFH = unfractionated heparin; VT = tidal volume. 
Time points for measurements were determined according to our previous findings that mediator activation occurs early in ventilator-induced lung 
injury, and neutrophil infiltration occurs later [14].Critical Care    Vol 13 No 4    Li et al.
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mild, <25% lung involvement; 2, moderate, 25% to 50% lung
involvement; 3, severe, 50% to 75% lung involvement; and 4,
very severe, >75% lung involvement.
Cell counts
Neutrophil counts were used to measure migration of neu-
trophils into the alveoli, as previously described [13]. Total cell
counts in lung-lavage fluid were performed by using a hemo-
cytometer. To perform cell differentials, cells were fixed on
glass slides by using cytospin and stained with geimsa.
Myeloperoxidase assay
The lungs (0.12 to 0.17 g) were homogenized in 5 ml of phos-
phate buffer (20 mmol/L, pH 7.4). One milliliter of the homoge-
nate was centrifuged at 10,000 g for 10 minutes at 4°C. The
resulting pellet was resuspended in 1 ml of phosphate buffer
(50 mmol/L, pH 6.0) containing 0.5% hexadecyltrimethylam-
monium bromide. The suspension was then subjected to three
cycles of freezing (on dry ice) and thawing (at room tempera-
ture), after which it was sonicated for 40 seconds and centri-
fuged again at 10,000 g for 5 minutes at 4°C. The supernatant
was assayed for MPO activity by measuring the hydrogen per-
oxide (H2O2)-dependent oxidation of 3,3', 5,5'-tetramethylben-
zidine (TMB). In its oxidized form, TMB has a blue color, which
was measured spectrophotometrically at 650 nm. The reac-
tion mixture for analysis consisted of a 25-μl tissue sample, 25
μl of TMB (final concentration, 0.16 mmol/L) dissolved in
dimethylsulfoxide, and 200 μl of H2O2 (final concentration,
0.30 mmol/L) dissolved in phosphate buffer (0.08 mol/L, pH
5.4). The reaction mixture was incubated for 3 minutes at
37°C, and the reaction was stopped by adding 1 ml of sodium
acetate (0.2 mol/L, pH 3.0), after which absorbance at 650 nm
was measured. The absorbance (A650) was reported as opti-
cal density (OD)/g of wet lung weight [13].
Measurement of PAI-1
At the end of the study period, the lungs were lavaged via tra-
cheostomy with a 20-gauge angiocatheter (sham instillation) 3
times with 0.6 ml of 0.9% normal saline. The effluents were
pooled and centrifuged at 2,000 rpm for 10 minutes. Superna-
tants were frozen at -80°C for further analysis of the cytokine.
PAI-1 with a lower detection limit of 0.02 ng/ml was measured
in serum and BAL fluid by using a commercially available
immunoassay kit containing primary polyclonal anti-mouse
antibody that was cross-reactive with rat and mouse PAI-1
(Molecular Innovations, Inc., Southfield, MI, USA). Each sam-
ple was run in duplicate according to the manufacturer's
instructions.
Reverse transcription-polymerase chain reaction (RT-
PCR)
For isolating total RNA, the lung tissues were homogenized in
TRIzol reagents (Invitrogen Corporation, Carlsbad, CA, USA)
according to the manufacturer's instructions. Total RNA (1 μg)
was reverse transcribed by using a GeneAmp PCR system
9600 (PerkinElmer, Life Sciences, Inc., Boston, MA, USA), as
previously described [18]. The following primers were used for
PAI-1: forward primer 5'-TCAGAGCAACAAGT TCAACTA-
CACTGAG-3'and reverse primer 5'-CCCACTGTCAAG-
GCTCCATCA CTTGCCCCA-3', and glyceraldehyde-
phosphate dehydrogenase (GAPDH) as internal control by
using the following primers: forward primer 5'-AATGCATCCT-
GCA CCACCAA-3' and reverse primer 5'-gtagccatattcattgt-
cata-3' (Integrated DNA Technologies, Inc., Coralville, IA,
USA) [19].
Immunohistochemistry
The lung tissues from control, nonventilated mice and mice
exposed to high-tidal-volume ventilation for 5 hours while
breathing room air were paraffin embedded, sliced at 4 μm,
deparaffinized, antigen unmasked in 10 mmol/L sodium citrate
(pH 6.0), incubated with rabbit anti-PAI-1 primary antibody
(1:100; New England BioLabs, Beverly, MA, USA) and bioti-
nylated goat anti-rabbit secondary antibody (1:100) according
to the manufacturer's instruction for an immunohistochemical
kit (Santa Cruz Biotechnology). The specimens were further
conjugated with horseradish peroxidase/streptavidin complex,
detected with a diaminobenzidine (DAB) substrate mixture,
and counterstained by hematoxylin. A dark-brown DAB signal,
identified by arrows, indicated positive staining of PAI-1 of epi-
thelial cells, whereas shades of light blue signified nonreactive
cells.
Statistical evaluation
The PAI-1 mRNAs were quantitated by using a National Insti-
tutes of Health (NIH) image analyzer, ImageJ 1.27z (National
Institutes of Health, Bethesda, MD, USA) and presented as
arbitrary units. Values were expressed as the mean ± SD for at
least six experiments. The data of lung wet- to dry-weight ratio,
total cell counts, neutrophils, PAI-1, MPO, and Evans blue dye
were conducted by using Statview 5.0 (Abascus Concepts,
Inc., Cary, NC, USA; SAS Institute, Inc.). All results of PAI-1
mRNA and MPO were normalized to control, nonventilated
mice breathing room air. ANOVA was used to assess the sta-
tistical significance of the differences, followed by multiple
comparisons with a Scheffé test, and a P value < 0.05 was
considered statistically significant.
Results
Physiological data
No statistical difference was found in pH, PaO2, PaCO2, mean
arterial pressure, and peak inspiratory pressure at the begin-
ning versus the end of 5 hours of mechanical ventilation (Table
2).
Inhibition of high-tidal-volume–induced microvascular 
leak, lung edema, and total lung injury with 
unfractionated heparin and enoxaparin
To determine the effects of mechanical ventilation on changes
of microvascular permeability and lung water in VILI, we meas-Available online http://ccforum.com/content/13/4/R108
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ured lung EBD and the wet- to dry-weight ratio (Figure 1). The
levels of lung EBD and wet- to dry-weight ratio significantly
increased in mice receiving VT 30 ml/kg mechanical ventilation
compared with those of either VT 6 ml/kg or control, nonventi-
lated mice. No significant elevation was found in mice venti-
lated with VT 6 ml/kg compared with control, nonventilated
mice. The increases of microvascular leak and lung edema
with VT  30 ml/kg mechanical ventilation were significantly
reduced by pharmacologic inhibition with unfractionated
heparin and enoxaparin. Low-dose unfractionated heparin and
enoxaparin were found to have better effects compared with
those of high-dose unfractionated heparin and enoxaparin.
Further to evaluate total lung injury, we measured alveolar con-
gestion, hemorrhage, infiltration of neutrophils into the air-
space or the vessel wall, and thickness of the alveolar wall.
Increases of lung injury with VT 30 ml/kg mechanical ventilation
were significantly reduced by pharmacologic inhibition with
unfractionated heparin and enoxaparin compared with those
of control, nonventilated mice and mice ventilated at VT 6 ml/
kg.
Inhibition of high-tidal-volume–induced neutrophil 
sequestration with unfractionated heparin and 
enoxaparin
Neutrophil counts were used to measure migration of neu-
trophils into the alveoli (Figure 2a). MPO assay was used to
quantitate total lung neutrophils (i.e., neutrophils marginated in
the vasculature, located in the parenchyma and in the alveoli
(Figure 2b). The neutrophil migration into lung lavage fluid and
MPO levels were significantly elevated in mice after mechani-
cal ventilation with VT 30 ml/kg for 5 hours compared with
mice ventilated with VT 6 ml/kg and control, nonventilated
mice. No significant elevation was found in mice ventilated
with VT 6 ml/kg compared with control, nonventilated mice.
The increases in lung inflammation, as measured by neu-
trophils in the bronchoalveolar lavage fluid and lung MPO
activity, with VT 30 ml/kg mechanical ventilation were signifi-
cantly reduced after pharmacologic inhibition with unfraction-
ated heparin and enoxaparin. Low-dose unfractionated
heparin and enoxaparin were found to have better effects com-
pared with those of high-dose unfractionated heparin and
enoxaparin.
Inhibition of high-tidal-volume-induced PAI-1 mRNA 
expression and PAI-1 production with unfractionated 
heparin and enoxaparin
To determine whether the increased neutrophil influx in mice
receiving VT 30 ml/kg mechanical ventilation was associated
with upregulation of chemotactic factors for neutrophils, we
measured PAI-1 mRNA expression and active PAI-1 protein
production for 1 and 5 hours of mechanical ventilation, respec-
tively (Figure 3). We found significantly increased ventilator-
induced PAI-1 mRNA expression and PAI-1 protein produc-
tion in the VT 30 ml/kg mice compared with those of VT 6 ml/
kg or control, nonventilated mice. No significant increase in
PAI-1 mRNA expression and PAI-1 protein production was
observed in the VT 6 ml/kg mice compared with control, non-
ventilated mice. This suggested that the increased expression
of PAI-1 protein production might have been responsible for
increased neutrophil infiltration. The increases in PAI-1 mRNA
expression and PAI-1 protein production with VT 30 ml/kg
mechanical ventilation were significantly reduced after phar-
macologic inhibition with unfractionated heparin and enoxa-
parin. Low-dose enoxaparin was found to have better effects
compared with those of high-dose unfractionated heparin and
enoxaparin.
PAI-1-deficient mice reduced lung stretch-induced lung 
injury, neutrophil sequestration, mRNA expression, and 
PAI-1 production
To determine the roles of PAI-1 activation in stretch-induced
lung injury, we used PAI-1-deficient mice (Figures 4, 5, 6 and
7). The microvascular permeability, lung edema, neutrophil
infiltration, PAI-1 mRNA expression, and PAI-1 protein produc-
tion in mice ventilated at VT 30 ml/kg for 5 hours were signifi-
cantly reduced with PAI-1-deficient mice. This suggested that
the reduction of high-tidal-volume-induced neutrophil influx
and lung injury by unfractionated heparin and enoxaparin was
dependent, in part, on the PAI-1 pathway. With immunohisto-
chemistry, we further confirmed the effectiveness of unfrac-
tionated heparin and enoxaparin in the inhibition of PAI-1
production and the roles of PAI-1 involved in VT 30 ml/kg ven-
tilator-induced lung injury in bronchial epithelial cells (Figure
7).
Discussion
High tidal volumes in normal animals have been used to mimic
the overdistention of the less-injured and thus more-compliant
Table 2
Physiological conditions at the beginning and end of 
ventilation
Nonventilated
Room air
VT 6 ml/kg
Room air
VT 30 ml/kg
Room air
PH 7.41 ± 0.04 7.36 ± 0.03 7.32 ± 0.05
PaO2 (mm Hg) 99.1 ± 0.4 82.6 ± 7.3 86.8 ± 1.2
PaCO2 (mm Hg) 40.3 ± 0.4 42.1 ± 1.5 35.1 ± 1.7
MAP (mm Hg)
Start 87 ± 1.6 85.7 ± 2.6 84.2 ± 2.1
End 85 ± 0.7 81.2 ± 1.9 73.6 ± 6.3
PIP, mm Hg
Start 9.7 ± 1.3 23.8 ± 2.5
End 11.8 ± 1.6 28.1 ± 3.4
Arterial blood gases and mean arterial pressure of normal 
nonventilated mice and mice ventilated at a tidal volume of 6 ml/kg or 
30 ml/kg for 5 hours (n = 10 per group). VT = tidal volume; MAP = 
mean arterial pressure; PIP = peak inspiratory pressure.Critical Care    Vol 13 No 4    Li et al.
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areas of lung found in ARDS patients. Dreyfuss and co-work-
ers [1] showed that hyperexpansion of the lung is the mecha-
nism of pulmonary edema in VILI. Fibrinolytic activity is
depressed in bronchoalveolar lavage fluids of patients with
acute lung injury (ALI)/ARDS. Our previous animal model of
lung fibrosis showed that simply overdistending lung tissue, in
the absence of any other stimuli, causes dysregulation of fibrin
turnover, but the mechanisms have been unclear [20]. As the
most common cause of death in ALI/ARDS is multiple-organ-
system failure, the systemic abnormalities of coagulation and
fibrinolysis may be an important therapeutic target over the
local pulmonary abnormalities. In a previous human study, ALI/
ARDS was characterized by decreased plasma levels of pro-
tein C and increased plasma levels of PAI-1 that are independ-
ent risk factors for mortality and adverse clinical outcomes
[21]. Heparin has been found to exert similar beneficial antiin-
flammatory activities as activated protein C [22]. Because
LMWHs have a longer half-life, high bioavailability, predictable
anticoagulant response, decreased risk of heparin-induced
thrombocytopenia, and decreased risk of osteoporosis, we
decided in this study to explore the role of LMWHs in the inhi-
bition of pulmonary inflammation compared with unfraction-
Figure 1
Unfractionated heparin and enoxaparin reduced lung stretch–induced microvascular leak, lung edema, and total lung injury Unfractionated heparin and enoxaparin reduced lung stretch-induced microvascular leak, lung edema, and total lung injury. The mice were ventilated 
at a tidal volume (VT) of 6 ml/kg (VT 6 ml) or 30 ml/kg (VT 30 ml) for 5 hours with room air. Unfractionated heparin, 200 IU/kg or 400 IU/kg, and enox-
aparin, 4 mg/kg or 8 mg/kg, was given subcutaneously 30 minutes before ventilation. (a) Evans blue dye (EBD) analysis of lung tissue (n = 6 per 
group). (b) Lung water measured by lung wet- to dry-weight ratio (n = 6 per group). (c) Total lung-injury scores of hematoxylin and eosin (H&E)-
stained paraffin sections (n = 6 per group). * P < 0.05 versus control, nonventilated mice; † P < 0.05 versus all other groups; ‡ P < 0.05 versus 200-
IU/kg or 4-mg/kg groups. H = unfractionated heparin; LMWH = enoxaparin.Available online http://ccforum.com/content/13/4/R108
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ated heparin [9]. In this mouse model of ALI, we found that
high-tidal-volume ventilation in mice led to increased microvas-
cular permeability, neutrophil influx, PAI-1 mRNA expression,
production of PAI-1, and positive staining of PAI-1 in epithe-
lium. Unfractionated heparin and enoxaparin regulated the
decrease of fibrinolytic activity.
Alveolar PAI-1 levels have been found to be associated with a
higher mortality rate in patients with ALI/ARDS [21]. Distur-
bances in coagulation and fibrinolysis, related to high pulmo-
nary concentrations of PAI-1, have been demonstrated in
patients with ALI/ARDS [23]. Others found that high-tidal-vol-
ume ventilation attenuated the fibrinolytic activity in rats pre-
treated with lipopolysaccharide (LPS), which was caused by
increased production or release or both of PAI-1 [24]. In a pre-
vious study of injurious mechanical ventilation in rats, alveolar
fibrinolytic capacity was suppressed because of local produc-
tion of PAI-1 in lung epithelial cells triggered by TGF-β1 [6]. In
our study, we found that high tidal volume increased lung
inflammation demonstrated by changes of microvascular per-
meability, lung edema, neutrophil infiltration, and production of
PAI-1. To define the role of PAI-1 production in stretch-
induced neutrophil migration into the alveoli, PAI-1–deficient
mice were used. In the setting of PAI-1 deficiency, neutrophils
may remain inappropriately adherent to the extracellular matrix
and unable to migrate into the alveolar compartment [25].
Shetty and co-workers [26] showed that regulation of uPA,
uPA receptors, and PAI-1 occurred at the posttranscriptional
level of mRNA stability regulated by p53 in lung epithelial cells.
Similar to the results of others, we found transcriptional regu-
lation of high-tidal-volume ventilation–induced PAI-1 mRNA
expression, which suggested that other mechanisms may be
involved in the regulation of PAI-1 production [11,27]. In addi-
tion to their anticoagulant activities, heparin and LMWH have
Figure 2
Unfractionated heparin and enoxaparin reduced lung stretch – induced neutrophil sequestration Unfractionated heparin and enoxaparin reduced lung stretch – induced neutrophil sequestration. The mice were ventilated at VT 6 ml or VT 30 ml for 
5 hours with room air. Unfractionated heparin, 200 IU/kg or 400 IU/kg, and enoxaparin, 4 mg/kg or 8 mg/kg, was given subcutaneously 30 minutes 
before ventilation. (a) Neutrophils in bronchoalveolar lavage (BAL) fluid of lung tissue (n = 6 per group). (b) Myeloperoxidase (MPO) assay of lung 
tissue (n = 6 per group). *P < 0.05 versus control, nonventilated mice; † P < 0.05 versus all other groups; ‡ P < 0.05 versus 200-IU/kg or 4-mg/kg 
groups. H = unfractionated heparin; LMWH = enoxaparin.Critical Care    Vol 13 No 4    Li et al.
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been found to modulate the production and release of inflam-
matory cytokines [10,22,28]. In several studies, heparin and
LMWH were shown to reduce lung edema and the chemotaxis
of neutrophils related to the inhibition of C5a [5,22]. In an in
vivo acute lung injury model in newborn piglets, heparin was
shown to improve gas exchange and severity of hyaline mem-
brane formation [28]. Heparin was shown to modulate migra-
tion of neutrophils, and the antiinflammatory effects of heparin
depended on the degree of sulfation of the heparin molecule.
Heparin also was found to be beneficial in the inhibition of PAI-
1 production [5]. In a previous porcine acute lung injury model,
LMWH was shown to attenuate neutrophil adhesion and TNF-
α activity [10]. In our study, we found that both unfractionated
heparin and enoxaparin reduced the high-tidal-volume-
induced lung injury, neutrophil sequestration, and production
of PAI-1. Previous study showed that low-dose heparin might
have favorable effects on survival [22]. In our study, we found
that low-dose unfractionated heparin and enoxaparin had bet-
Figure 3
Unfractionated heparin and enoxaparin reduced stretch-induced plasminogen activator inhibitor-1 (PAI-1) mRNA expression and protein production Unfractionated heparin and enoxaparin reduced stretch-induced plasminogen activator inhibitor-1 (PAI-1) mRNA expression and protein production. 
The mice were ventilated at VT 6 ml or VT 30 ml for 1 hour with room air. Unfractionated heparin, 200 IU/kg or 400 IU/kg, and enoxaparin, 4 mg/kg or 
8 mg/kg, was given subcutaneously 30 minutes before ventilation. (a) Reverse transcription-polymerase chain reaction (RT-PCR) assay was per-
formed for PAI-1 mRNA (a, top panel), glyceraldehydes-phosphate dehydrogenase (GAPDH) mRNA (a, middle panel), and arbitrary units (a, bottom 
panel) (n = 6 per group). Arbitrary units were expressed as the ratio of PAI-1 mRNA to GAPDH. (b) Active PAI-1 production in BAL fluid. *P < 0.05 
versus control, nonventilated mice; † P < 0.05 versus all other groups; ‡ P < 0.05 versus 200-IU/kg or 4-mg/kg groups. H = unfractionated heparin; 
LMWH = enoxaparin.Available online http://ccforum.com/content/13/4/R108
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ter effects in reducing lung injury associated with an increase
of neutrophil infiltration, but no significant differences in PAI-1
production were found between different heparin treatments.
This inconsistency may be due to induction of PAI-1 by many
proinflammatory factors and different cells, including platelets,
fibroblasts, resident monocytes/macrophages, and endothe-
lial and airway epithelial cells [4]. Higher doses of heparin/
LMWH caused more bleeding complications (scoring of alve-
olar hemorrhage, as described in Methods: VT 30 ml/kg with
low-dose unfractionated heparin = 1.4 ± 0.4 versus VT 30 ml/
kg with high-dose unfractionated heparin = 2.5 ± 0.5; VT 30
ml/kg with low-dose enoxaparin = 1.3 ± 0.3 versus VT 30 ml/
kg with high-dose enoxaparin = 3.1 ± 0.6) and induced proin-
flammatory effects because of the decrease of endothelial
nitric oxide production and promotion of cell adhesion and
platelet aggregation [22]. In a previous study of acute lung
Figure 4
PAI-1–deficient mice reduced lung stretch–induced microvascular  leak, lung edema, and total lung injury PAI-1–deficient mice reduced lung stretch–induced microvascular 
leak, lung edema, and total lung injury. Wild-type or PAI-1-/- mice were 
ventilated at VT 30 ml for 5 hours with room air. (a) EBD analysis of lung 
tissue (n = 6 per group). (b) Lung water measured by lung wet- to dry-
weight ratio (n = 6 per group). (c) Total lung-injury scores of H&E-
stained paraffin sections (n = 6 per group). * P < 0.05 versus control, 
nonventilated mice; † P < 0.05 versus PAI-1-/- mice. EBD = Evans blue 
dye; PAI-1 = plasminogen-activator inhibitor-1.
Figure 5
Plasminogen-activator inhibitor-1 (PAI-1)-deficient mice reduced lung  stretch–induced neutrophil sequestration Plasminogen-activator inhibitor-1 (PAI-1)-deficient mice reduced lung 
stretch–induced neutrophil sequestration. Wild-type or PAI-1-/- mice 
were ventilated at VT 30 ml for 5 hours with room air. (a) Neutrophils in 
bronchoalveolar lavage fluid of lung tissue (n = 6 per group). (b) MPO 
assay of lung tissue (n = 6 per group). *P < 0.05 versus control, non-
ventilated mice; † P < 0.05 versus PAI-1-/- mice.Critical Care    Vol 13 No 4    Li et al.
Page 10 of 12
(page number not for citation purposes)
injury in human, PAI-1 antigen levels in both plasma and
edema fluid were higher in patients with ALI, and differences
in PAI-1 activity were concordant with levels of PAI-1 antigen
[21]. Others showed that PAI-1 levels in plasma and pulmo-
nary edema samples from patients with ALI/ARDS were asso-
ciated with higher mortality rates [21]. In our study, we found
that high-tidal-volume ventilation induced more increased PAI-
1 activity in BAL fluid compared with those in plasma (fivefold
versus twofold as compared with control, nonventilated mice).
Unfractionated heparin and enoxaparin reduced high-tidal-vol-
ume-induced PAI-1 production in BAL fluid but not in plasma.
This result and the studies of others suggested that PAI-1 pro-
duction after injurious mechanical ventilation was in large part
due to local activation of the fibrinolytic system [6,21,23]. Acti-
vation of coagulation and inhibition of fibrinolysis have been
shown to be a local process because no systemic inhibition of
fibrinolysis was found, and levels of coagulation and fibrinoly-
sis markers were much higher in the pulmonary compartment
than were the systemic levels [29].
Findings in other studies supported our results that neutrophil
infiltration and the development of acute lung injury involved
the PAI-1 pathway in an isolated mouse model of endotoxemia
[25,30]. Previous in vivo study of LPS-pretreated mice
showed that PAI-1 regulated neutrophil recruitment to inflam-
matory foci via  mitogen-activated protein kinase pathways
[25]. In an in vitro study of bovine aortic endothelium, others
showed that Akt negatively regulated PAI-1 expression
through the downregulation of P38/extracellular signal-regu-
lated kinase1/2 pathways [31]. Experimental acute lung injury
model of rat showed that local lung angiotensin II was involved
in the pathogenesis of disordered coagulation of PAI-1 pro-
duction in VILI [11]. In the study of patients with ARDS, others
showed that alveolar epithelial cells can activate protein C,
and the ability to activate protein C was diminished in
response to exposure to proinflammatory cytokines, including
PAI-1 [32]. Previous study also showed that markers of dys-
regulated coagulation and fibrinolysis, such as IL-8, intercellu-
lar adhesion molecule 1, and protein C, are predictive of
clinical outcomes in patients with ALI/ARDS [30]. Heparin
may inhibit pulmonary coagulation by affecting other cell types
in the lung, including endothelial cells and fibroblasts. Both
heparin and LMWH have been shown to inhibit the activation
of nuclear factor-κB and attenuated endothelial dysfunction by
enhancing nitric oxide [22]. Heparin and LMWH can also
inhibit neutrophil adhesion to P-selectin in vitro and modulate
the hemodynamic effects of platelet-activating factor (PAF)
and thromboxane B2  biosynthesis  in vivo, suggesting the
mechanism of altering endothelial P-selectin/PAF [10]. With
immunohistochemistry, we confirmed the effects of unfraction-
ated heparin and enoxaparin on the increase of PAI-1 staining
in mice ventilated at VT 30 ml/kg in the bronchial epithelia but
not in endothelial cells. The discrepancies of cell types
involved may be due to the different physical forces of
mechanical strain and immunohistochemistry method limita-
tions. Activated protein C associated with high mortality in
patients with ARDS was not measured in this study because
of unavailability of a commercial immunoassay kit for mice.
Figure 6
Plasminogen-activator inhibitor-1 (PAI-1)-deficient mice reduced lung  stretch–induced mRNA expression and PAI-1 production Plasminogen-activator inhibitor-1 (PAI-1)-deficient mice reduced lung 
stretch–induced mRNA expression and PAI-1 production. Wild-type or 
PAI-1-/- mice were ventilated at VT 30 ml for 1 hour with room air. (a) 
RT-PCR assay was performed for PAI-1 mRNA (a, top panel), glyceral-
dehydes-phosphate dehydrogenase (GAPDH) mRNA (a, middle 
panel), and arbitrary units (a, bottom panel) (n = 6 per group). Arbitrary 
units are expressed as the ratio of PAI-1 mRNA to GAPDH. (b) Active 
PAI-1 production in BAL fluid (n = 6 per group). *P < 0.05 versus con-
trol, nonventilated mice; † P < 0.05 versus PAI-1-/- mice.Available online http://ccforum.com/content/13/4/R108
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Conclusions
Although the ARDS network trial demonstrated that low- is
safer than high-tidal-volume ventilation, these findings have
been questioned. In the combined rat model of VILI and acid
aspiration, VT 3 ml/kg was more protective than 6 ml/kg, so
even very low VT of 6 ml/kg can cause lung injury. The National
Heart, Lung and Blood Institute working group on acute lung
injury identified examination of the biology of stress-induced
injury to the lung in health and disease as a fertile area of future
research, because ventilation-induced release of cytokines
may lead to systemic translocation and multisystem organ fail-
ure [33,34]. With an in vivo mouse model of acute lung injury,
we demonstrated that high-tidal-volume mechanical ventilation
increased microvascular permeability, neutrophil influx, lung
PAI-1 mRNA expression, production of active PAI-1, and the
deleterious effects were attenuated by low-dose unfraction-
ated heparin or enoxaparin treatment. These results imply that
dysregulated coagulation and fibrinolysis are involved in the
pathogenesis of VILI and that the protective mechanism of
heparin/LMWH attenuation of VILI may be related to a reduc-
tion in PAI-1. In addition to the lung-protective strategy used in
the management of patients with ALI, our data added to the
understanding of the effects of mechanical forces in the lung
and may permit possible strategies directed at preventing VILI
to be instituted early in the course of the disease process.
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Key messages
￿  High-tidal-volume ventilation increased plasminogen 
activator inhibitor-1 in acute lung injury.
￿  Inhibition of plasminogen activator inhibitor-1 by unfrac-
tionated heparin and enoxaparin may offer new treat-
ment options for patients with severe ARDS.
Figure 7
Unfractionated heparin, enoxaparin, and PAI-1-deficient mice reduced stretch-induced PAI-1 activation Unfractionated heparin, enoxaparin, and PAI-1-deficient mice reduced stretch-induced PAI-1 activation. Representative photomicrographs (×400) 
with PAI-1 staining of paraffin lung sections with immunohistochemistry were from mice ventilated at VT 6 ml or VT 30 ml for 5 hours with room air. 
Unfractionated heparin, 200 IU/kg or 400 IU/kg, and enoxaparin, 4 mg/kg or 8 mg/kg, was given subcutaneously 30 minutes before ventilation (n = 
6 per group). (a) Control wild-type mice; (b) VT 6 ml/kg wild-type mice; (c) VT 30 ml/kg wild-type mice; (d) VT 30 ml/kg wild-type mice pretreated 
with 200 IU unfractionated heparin; (e) VT 30 ml/kg wild-type mice pretreated with 400 IU unfractionated heparin; (f) VT30 ml/kg PAI-1-/- mice; (g) VT 
30 ml/kg wild-type mice pretreated with 4 mg/kg enoxaparin; and (h) VT 30 ml/kg wild-type mice pretreated with 8 mg/kg enoxaparin. A dark brown 
diaminobenzidine (DAB) signal identified by arrows indicates positive staining for PAI-1 in the lung epithelium or interstitial, whereas shades of bluish 
tan signify nonreactive cells.Critical Care    Vol 13 No 4    Li et al.
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